DermTech (DMTK)
(Delayed Data from NSDQ)
$0.60 USD
+0.02 (3.02%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.60 0.00 (-0.51%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
DMTK 0.60 +0.02(3.02%)
Will DMTK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DMTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DMTK
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
DocGo Inc. (DCGO) Q4 Earnings Lag Estimates
DMTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
Medpace (MEDP) Surpasses Q2 Earnings and Revenue Estimates
Other News for DMTK
What Analysts Are Saying About DermTech Stock
DermTech just downgraded at Lake Street, here's why
DermTech (DMTK) was downgraded to a Hold Rating at BTIG
DermTech just downgraded at BTIG, here's why
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan